´ÜÀϱâ°ü¿¡¼­ÀÇ Ç×Ç÷¼ÒÆÇÁ¦ º¹¿ë ȯÀÚ¿¡¼­ ´©µÎÀý°³¼úÀÇ °æÇè: °á°ú, ¾ÈÁ¤¼º ¹× ÇÕº´Áõ
A Single Institution¡¯s Experience of Infundibulotomy in Patients Taking Antiplatelet Agents: Outcomes, Safety and Complications

´ëÇѼÒÈ­±âÇÐȸÁö 2014³â 63±Ç 4È£ p.216 ~ p.222

¹éµ¿ÈÆ(Baek Dong-Hoon) - ºÎ»ê´ëÇб³ Àǰú´ëÇÐ ºÎ»ê´ëÇб³º´¿ø ³»°úÇб³½Ç
¼Û±Ù¾Ï(Song Geun-Am) - ºÎ»ê´ëÇб³ Àǰú´ëÇÐ ºÎ»ê´ëÇб³º´¿ø ³»°úÇб³½Ç
±èµ¿¿í(Kim Dong-Uk) - ºÎ»ê´ëÇб³ Àǰú´ëÇÐ ºÎ»ê´ëÇб³º´¿ø ³»°úÇб³½Ç
±è±¤ÇÏ(Kim Gwang-Ha) - ºÎ»ê´ëÇб³ Àǰú´ëÇÐ ºÎ»ê´ëÇб³º´¿ø ³»°úÇб³½Ç
À̺ÀÀº(Lee Bong-Eun) - ºÎ»ê´ëÇб³ Àǰú´ëÇÐ ºÎ»ê´ëÇб³º´¿ø ³»°úÇб³½Ç
ÀüÇý°æ(Jeon Hye-Kyung) - ºÎ»ê´ëÇб³ Àǰú´ëÇÐ ºÎ»ê´ëÇб³º´¿ø ³»°úÇб³½Ç
ÁöÁØÇü(Jhi Joon-Hyung) - ºÎ»ê´ëÇб³ Àǰú´ëÇÐ ºÎ»ê´ëÇб³º´¿ø ³»°úÇб³½Ç
¹èÁ¤È£(Bae Jung-Ho) - ºÎ»ê´ëÇб³ Àǰú´ëÇÐ ºÎ»ê´ëÇб³º´¿ø ³»°úÇб³½Ç
ÀÌÇöÁ¤(Lee Hyun-Jeong) - ºÎ»ê´ëÇб³ Àǰú´ëÇÐ ºÎ»ê´ëÇб³º´¿ø ³»°úÇб³½Ç

Abstract

¸ñÀû: ³»½Ã°æ¿ªÇà´ãÃé°üÁ¶¿µ¼ú(ERCP)¸¦ ½ÃµµÇϸ鼭 »ð°üÀÌ ¾î·Á¿î °æ¿ì ħÇüÀý°³µµ¸¦ ÀÌ¿ëÇÑ ´©µÎÀý°³¼ú(infundibulotomy) ÀÌ ½ÃÇàµÈ´Ù. Àα¸ÀÇ °í·ÉÈ­¿Í ½ÉÇ÷°üÁúȯÀÇ ¹ß»ý·üÀÌ Áõ°¡Çϸ鼭 Ç×Ç÷¼ÒÆÇÁ¦¸¦ º¹¿ëÇϴ ȯÀÚ°¡ ´Ã°í ÀÖ´Ù. ¶ÇÇÑ Ãé´ãµµ ÁúȯÀÇ Áø´Ü°ú Ä¡·áÀÇ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â ERCPÀÇ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ´Ù. ÇÏÁö¸¸ Ç×Ç÷¼ÒÆÇÁ¦¸¦ º¹¿ëÇϴ ȯÀÚ¿¡ ¼­ ´©µÎÀý°³¼ú¿¡ ´ëÇÑ ¿¬±¸´Â ¸Å¿ì ºÎÁ·ÇÑ »óÅÂÀÌ´Ù. À̹ø ¿¬ ±¸¿¡¼­´Â Ç×Ç÷¼ÒÆÇÁ¦¸¦ º¹¿ëÇϴ ȯÀÚ¿¡¼­ ´©µÎÀý°³¼úÀÇ ¾È Àü¼º ¹× ÇÕº´Áõ¿¡ ´ëÇØ ¾Ë¾Æº¸°íÀÚ ÇÏ¿´´Ù.

´ë»ó ¹× ¹æ¹ý: 2011³â 1¿ùºÎÅÍ 2012³â 12¿ù±îÁö ºÎ»ê´ëÇб³ º´¿ø ¼ÒÈ­±â³»°ú¿¡¼­ ERCP¸¦ ½ÃÇàÇÑ ÃÑ 835¸í ȯÀÚ¸¦ ´ë»ó À¸·Î Àǹ«±â·ÏÀ» ÈÄÇâÀûÀ¸·Î °ËÅäÇÏ¿© ºÐ¼®ÇÏ¿´´Ù. ÀÌ Áß ÀÀ ±ÞÀ¸·Î ´ã°ü ¹è¾×À» ½ÃÇàÇÑ 72¸íÀÇ È¯ÀÚ°¡ ½Ã¼ú Àü Ç×Ç÷¼ÒÆÇ Á¦¸¦ º¹¿ëÇÑ º´·ÂÀÌ ÀÖ¾ú°í, ±× Áß 20¸íÀº ´©µÎÀý°³¼úÀ» ½ÃÇà ÇÑ ±ºÀ̾úÀ¸¸ç ³ª¸ÓÁö 52¸íÀº ´©µÎÀý°³¼úÀ» ½ÃÇàÇÏÁö ¾ÊÀº ±ºÀ̾ú´Ù. °¢ ±º¿¡¼­ ÃâÇ÷, ÃéÀå¿°, õ°ø µîÀÇ ÇÕº´ÁõÀ» Á¶»çÇÏ ¿´´Ù.

°á°ú: ´©µÎÀý°³¼úÀ» ½ÃÇàÇÑ ±º°ú ½ÃÇàÇÏÁö ¾ÊÀº ±º °£¿¡ ¿¬·É, ¼ºº°, Ç×Ç÷¼ÒÆÇÁ¦ Á¾·ù, ±âÀúÁúȯ, Ç÷¾×ÇÐÀû °Ë»ç ¹× À¯µÎ ÁÖ À§ °Ô½Ç À¯¹«´Â Åë°èÀûÀ¸·Î À¯ÀÇÇÑ Â÷À̸¦ º¸ÀÌÁö ¾Ê¾Ò´Ù. µÎ ±º ¸ðµÎ¿¡¼­ ¼º°øÀûÀ¸·Î ´ã°ü »ð°ü ¹× ´ã°ü ¹è¾×À» ½ÃÇàÇÏ¿´ ´Ù. ÀÓ»óÀûÀ¸·Î ÀÇ¹Ì ÀÖ´Â ÃâÇ÷Àº ´©µÎÀý°³¼úÀ» ½ÃÇàÇÑ ±º¿¡ ¼­ 1¿¹(5%, 1/20¿¹)°¡ °üÂûµÇ¾úÀ¸¸ç ´©µÎÀý°³¼úÀ» ½ÃÇàÇÏÁö ¾ÊÀº ±º¿¡¼­´Â ¹ß°ßµÇÁö ¾Ê¾Ò´Ù. ÇÏÁö¸¸ µÎ ±º °£¿¡ Åë°èÀûÀ¸ ·Î À¯ÀÇÇÑ Â÷ÀÌ´Â ¾ø¾ú´Ù. ERCP ÈÄ ÃéÀå¿°Àº ´©µÎÀý°³¼úÀ» ½ÃÇàÇÑ ±º¿¡¼­ 2¿¹(10%, 2/20¿¹), ´©µÎÀý°³¼úÀ» ½ÃÇàÇÏÁö ¾Ê Àº ±º¿¡¼­ 7¿¹(13.5%, 7/52¿¹)·Î µÎ ±º °£¿¡ À¯ÀÇÇÑ Â÷À̸¦ º¸ÀÌÁö ¾Ê¾Ò´Ù(p=0.691). µÎ ±º ¸ðµÎ¿¡¼­ õ°øÀº ¹ß°ßµÇÁö ¾Ê ¾Ò´Ù.

°á·Ð: Ç×Ç÷¼ÒÆÇÁ¦¸¦ º¹¿ëÇϰí Àִ ȯÀÚ¿¡¼­ ´©µÎÀý°³¼úÀº ERCP ÇÕº´ÁõÀ» Áõ°¡½ÃŰÁö ¾Ê¾Æ, Ç×Ç÷¼ÒÆÇÁ¦¸¦ º¹¿ëÇϰí ÀÖ ´Â ȯÀÚ¿¡¼­µµ ºñ±³Àû ¾ÈÀüÇÏ°Ô ½ÃÇàÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î ÆÇ´Ü µÈ´Ù.
Background/Aims: The diagnostic and therapeutic utility of endoscopic retrograde cholangiopancreatography (ERCP) has been well demonstrated for biliary and pancreatic diseases. Biliary access can be allowed by infundibulotomy if failed by using the standard cannulation methods. However, no data are available regarding ERCP-related complications in patients taking antiplatelet agents who are undergoing infundibulotomy. Therefore, we aimed to assess the frequency of ERCP-related complications after infundibulotomy in patients taking antiplatelet agents.

Methods: We performed a retrospective study, and enrolled 835 patients who underwent ERCP at Pusan National University Hospital from January 2011 to December 2012. Seventy-two patients had been taking antiplatelet agents prior to the procedure. Patients were classified into two groups according to the utilization of infundibulotomy: 20 patients underwent infundibulotomy (group 1), and 52 patients did not undergo infundibulotomy (group 2). Complications after ERCP were defined as bleeding, post-ERCP pancreatitis, and perforation according to Cotton¡¯s criteria.

Results: Between group 1 and 2, there were no significant differences in baseline characteristics. ERCP was successfully performed in all cases. Clinically significant bleeding was observed in one patient in group 1 (5%, 1/20) versus none in group 2. Post-ERCP pancreatitis was observed in 2 patients (10.0%, 2/20) in group 1, and 7 patients (13.5%, 7/52) in group 2 (p=0.691). However, none of these differences were statistically significant. No perforation occurred in both groups.

Conclusions: Considering the low incidence of bleeding after infundibulotomy in patients taking antiplatelet agents, infundibulotomy may be safely performed in this group of patients.

Ű¿öµå

³»½Ã°æ¿ªÇà´ãÃé°üÁ¶¿µ¼ú, Ç×Ç÷¼ÒÆÇÁ¦, ´©µÎÀý°³¼ú, ÇÕº´Áõ
Endoscopic retrograde cholangiopancreatography, Antiplatelet agents, Infundibulotomy, Complications
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
MEDLINE ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Ű¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆÇ³âµµ(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå